How to Make a Regenerative Medicine
Regenerative medicine has long carried the aura of the mythic, from Prometheus’s eternally renewing liver to Wolverine’s capacity for accelerated repair.
15th July 2026
Sarcopenia Market and Landscape
Sarcopenia represents one of the largest remaining untapped pharmaceutical markets. Defined by the progressive loss of skeletal muscle mass, strength, and physical performance with aging or chronic disease, it affects tens of millions of adults worldwide and drives enormous healthcare costs through falls, frailty, loss of independence, and increased mortality. This document outlines the current market and landscape of Sarcopenia, including the opportunities, challenges and strategic implications.
26th June 2026
Istesso initiates Phase 2 clinical trial of leramistat in sarcopenia
London, UK, 16th June 2026. Istesso, the leader in oral...
16th June 2026
Istesso presents data showing that its first-in-class oral regenerative agent, leramistat, restores muscle quality beyond baseline in aging models
Leramistat, a first-in-class mitochondrial complex I modulator (MCM),[1],[2] improves muscle...
22nd April 2026
Istesso strengthens leadership team with appointment of Head of Translational Science
Istesso, the company developing the first oral regenerative medicines, today...
2nd March 2026
Istesso’s ground-breaking research hits the headlines
Recent press coverage of our work to develop healthspan-extending drugs recognises their potential to offer “a more sustainable path to healthier, longer lives”
4th December 2025
Istesso provides updates on leramistat and next-generation programs
Advancement of leramistat, a first-in-class mitochondrial complex I modulator (MCM),...
26th November 2025
Ground-breaking data demonstrates tissue repair with Istesso’s novel investigational medicines
Istesso’s new class of developmental drugs, which inhibit mitochondrial complex...
17th July 2025
Istesso appoints Dr Mike Owen to Board of Directors
Istesso, the leading adaptive tissue-repair company, is pleased to announce...
4th June 2025